UK’s Preparation for a No Deal Brexit

by | Apr 5, 2019 | Brexit, EU, Medical Devices

With the initial Brexit plans derailed and the deadline now being extended to April 12th, the trade and manufacturing industry is in a state of chaos. The constantly changing regulations have put the stakeholders in a difficult situation. In preparation for what appears to be concluding in a no deal Brexit, the British Government has been releasing a multitude of guidance documents.

This time the UK government released guidance on conditional marketing authorization (CMA) applications, marketing authorizations in exceptional circumstances, and scientific advice and a webinar to guide medical device companies on how to make regulatory submissions in case of a no deal scenario to the MHRA (Medicines and Healthcare products Regulatory Agency). You can view the webinar slides here:1

The Conditional Marketing Authorization (CMA) guidance states that MHRA will grant a CMA for a product that promises to fulfill an unmet medical need like in cases of products that treat serious and life-threatening diseases or when the product offers a major medical advantage. A CMA is granted with the condition that the clinical data is not yet complete, but the company is in the process of gathering such data and submitting it to the MHRA.2

However, the Marketing Authorization Application of the product must still contain relevant and adequate information to prove the safety and efficacy of the device along with a positive risk-benefit analysis. The company must also justify their intent of obtaining a CMA and clearly indicate what clinical studies are underway and when the data will become available.

A CMA will be valid for a year and will be renewable annually. The decision to grant a CMA completely rests with the MHRA and can be rejected if the MHRA determines that the risk-benefit analysis for the product is negative.3

Likewise, for the Marketing Authorization under Exceptional Circumstances, MHRA will grant this authorization only for products where obtaining clinical data is difficult because the condition being treated is rare or obtaining full information is not possible or unethical.2

However, such authorizations will likely be subjected to specific obligations such as periodic surveillance of the post-market data on the safety and efficacy of the device.

What is interesting to see is all of these regulations are strongly based on the EU scheme and so are most of the other guidance documents. April 12th is finally the deadline for the UK to decide, since April 12th is the deadline for the UK to decide whether to hold European elections. If the UK is still not able to make up their mind, chances are that the UK will have to leave the EU without a deal.

We are closely monitoring the Brexit activities and will keep the medical device community abreast regarding the changing regulations.

If you have any questions about marketing your medical device in the EU, call us at 248-987-4497 or email us at

1Gov.UK (March 2019) Webinars related to making submissions to the MHRA if the UK leaves the EU with no deal retrieved on 04/02/2019 from

2Gov.UK (March 2019 Conditional Marketing Authorisations, exceptional circumstances Marketing Authorisations and national scientific advice in a no deal scenario retrieved on 04/02/2019 from

3RAPS (March 2019) MHRA Offers More No-Deal Brexit Guidance on Conditional Marketing Authorizations retrieved on 04/02/2019 from


Nikita Angane

Nikita Angane

Solutions Delivery Specialist - Ms. Angane is a Bioengineering graduate with experience in medical device commercialization, product development, quality system compliance and regulatory affairs. Her portfolio includes working on medical devices, combination products, and pharmaceuticals. As a Solutions Delivery Specialist at EMMA International, she offers her expertise to help our clients achieve an effective and sustainable quality system, and develop regulatory strategies for market access and compliance of new products in the US and international markets. Ms. Angane earned a Bachelor of Engineering in Biomedical Engineering from the University of Mumbai, India and an M.S. in Bioengineering from University of Illinois at Chicago.

More Resources

Change Management And Control

Change Management And Control

One of the biggest and most important aspects of quality management is a system to monitor changes and how they impact the product. Change management is an approach for changing processes or products in a way which adheres to regulatory standards by ensuring stability and consistency throughout processes. It applies across all changes within a process and throughout an entire products life cycle.
Aseptic Technique and Gowning

Aseptic Technique and Gowning

One of the most common techniques to prevent contamination of products and reduce quality impacts in the pharmaceutical industry is called aseptic gowning. Humans are the biggest sources of microbial contamination in cleanroom environments and therefore proper gowning procedures are essential to ensuring product quality. Proper training, education, hygiene, qualification, and authorization must be put in place and be required for entry to all clean room environments...
Importance of Pharmaceutical GMP

Importance of Pharmaceutical GMP

Having high quality standards is vital to any organization but is even more essential in the pharmaceutical industry. Practices that are governed by these standards are commonly called Good Manufacturing Practices (GMP) and ensure consistent and controlled production of products. These practices govern all aspects and procedures within production and provide documented proof that procedures are consistently followed during the manufacturing processes every time products are made. They are designed to minimize risks throughout the manufacturing process that are not able to be eliminated in final product testing so that pharmaceuticals are safe for use...

Ready to learn more about working with us?

Pin It on Pinterest

Share This